These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 31332011)

  • 1. Drugging an undruggable pocket on KRAS.
    Kessler D; Gmachl M; Mantoulidis A; Martin LJ; Zoephel A; Mayer M; Gollner A; Covini D; Fischer S; Gerstberger T; Gmaschitz T; Goodwin C; Greb P; Häring D; Hela W; Hoffmann J; Karolyi-Oezguer J; Knesl P; Kornigg S; Koegl M; Kousek R; Lamarre L; Moser F; Munico-Martinez S; Peinsipp C; Phan J; Rinnenthal J; Sai J; Salamon C; Scherbantin Y; Schipany K; Schnitzer R; Schrenk A; Sharps B; Siszler G; Sun Q; Waterson A; Wolkerstorfer B; Zeeb M; Pearson M; Fesik SW; McConnell DB
    Proc Natl Acad Sci U S A; 2019 Aug; 116(32):15823-15829. PubMed ID: 31332011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugging all RAS isoforms with one pocket.
    Kessler D; Bergner A; Böttcher J; Fischer G; Döbel S; Hinkel M; Müllauer B; Weiss-Puxbaum A; McConnell DB
    Future Med Chem; 2020 Nov; 12(21):1911-1923. PubMed ID: 32779487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele.
    Zhang Y; Larraufie MH; Musavi L; Akkiraju H; Brown LM; Stockwell BR
    Biochemistry; 2018 Feb; 57(8):1380-1389. PubMed ID: 29313669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
    Hoshiyama H
    Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS
    Bröker J; Waterson AG; Smethurst C; Kessler D; Böttcher J; Mayer M; Gmaschitz G; Phan J; Little A; Abbott JR; Sun Q; Gmachl M; Rudolph D; Arnhof H; Rumpel K; Savarese F; Gerstberger T; Mischerikow N; Treu M; Herdeis L; Wunberg T; Gollner A; Weinstabl H; Mantoulidis A; Krämer O; McConnell DB; W Fesik S
    J Med Chem; 2022 Nov; 65(21):14614-14629. PubMed ID: 36300829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
    Roskoski R
    Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
    Nyíri K; Koppány G; Vértessy BG
    Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling receptor flexibility in the structure-based design of KRAS
    Zhu K; Li C; Wu KY; Mohr C; Li X; Lanman B
    J Comput Aided Mol Des; 2022 Aug; 36(8):591-604. PubMed ID: 35930206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugging KRAS: current perspectives and state-of-art review.
    Parikh K; Banna G; Liu SV; Friedlaender A; Desai A; Subbiah V; Addeo A
    J Hematol Oncol; 2022 Oct; 15(1):152. PubMed ID: 36284306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for Targeting KRAS: A Challenging Drug Target.
    Wadood A; Ajmal A; Rehman AU
    Curr Pharm Des; 2022; 28(23):1897-1901. PubMed ID: 35524675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR in integrated biophysical drug discovery for RAS: past, present, and future.
    Marshall CB; KleinJan F; Gebregiworgis T; Lee KY; Fang Z; Eves BJ; Liu NF; Gasmi-Seabrook GMC; Enomoto M; Ikura M
    J Biomol NMR; 2020 Nov; 74(10-11):531-554. PubMed ID: 32804298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations.
    Oyedele AK; Ogunlana AT; Boyenle ID; Ibrahim NO; Gbadebo IO; Owolabi NA; Ayoola AM; Francis AC; Eyinade OH; Adelusi TI
    Mol Divers; 2023 Aug; 27(4):1795-1807. PubMed ID: 36271195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation.
    Yin G; Kistler S; George SD; Kuhlmann N; Garvey L; Huynh M; Bagni RK; Lammers M; Der CJ; Campbell SL
    J Biol Chem; 2017 Mar; 292(11):4446-4456. PubMed ID: 28154176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Acquired Resistance to KRAS
    Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
    Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glimmers of hope for targeting oncogenic KRAS-G12D.
    Tang D; Kang R
    Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS.
    Yin G; Huang J; Petela J; Jiang H; Zhang Y; Gong S; Wu J; Liu B; Shi J; Gao Y
    Signal Transduct Target Ther; 2023 May; 8(1):212. PubMed ID: 37221195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
    Tang D; Kroemer G; Kang R
    Mol Cancer; 2021 Oct; 20(1):128. PubMed ID: 34607583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure of NRAS Q61K with a ligand-induced pocket near switch II.
    Gebregiworgis T; Chan JY; Kuntz DA; Privé GG; Marshall CB; Ikura M
    Eur J Cell Biol; 2024 Jun; 103(2):151414. PubMed ID: 38640594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico comparative analysis of KRAS mutations at codons 12 and 13: Structural modifications of P-Loop, switch I&II regions preventing GTP hydrolysis.
    Gerber M; Goel S; Maitra R
    Comput Biol Med; 2022 Feb; 141():105110. PubMed ID: 34920161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS: From undruggable to a druggable Cancer Target.
    Uprety D; Adjei AA
    Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.